<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The effect of <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> on splanchnic <z:chebi fb="105" ids="17234">glucose</z:chebi> uptake (SGU), endogenous <z:chebi fb="105" ids="17234">glucose</z:chebi> production (EGP), and hepatic fat content was studied in 14 type 2 diabetic patients (age 50 +/- 2 years, BMI 29.4 +/- 1.1 kg/m(2), HbA(1c) 7.8 +/- 0.4%) </plain></SENT>
<SENT sid="1" pm="."><plain>Hepatic fat content (magnetic resonance spectroscopy) and SGU (oral <z:chebi fb="105" ids="17234">glucose</z:chebi> load- insulin clamp technique) were quantitated before and after <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> (45 mg/day) therapy for 16 weeks </plain></SENT>
<SENT sid="2" pm="."><plain>Subjects received a 7-h euglycemic insulin (100 mU </plain></SENT>
<SENT sid="3" pm="."><plain>m(-2) </plain></SENT>
<SENT sid="4" pm="."><plain>min(-1)) clamp, and a 75-g oral <z:chebi fb="105" ids="17234">glucose</z:chebi> load was ingested 3 h after starting the insulin clamp </plain></SENT>
<SENT sid="5" pm="."><plain>Following <z:chebi fb="105" ids="17234">glucose</z:chebi> ingestion, the steady-state <z:chebi fb="105" ids="17234">glucose</z:chebi> infusion rate during the insulin clamp was decreased appropriately to maintain euglycemia </plain></SENT>
<SENT sid="6" pm="."><plain>SGU was calculated by subtracting the integrated decrease in <z:chebi fb="105" ids="17234">glucose</z:chebi> infusion rate during the 4 h after <z:chebi fb="105" ids="17234">glucose</z:chebi> ingestion from the ingested <z:chebi fb="105" ids="17234">glucose</z:chebi> load </plain></SENT>
<SENT sid="7" pm="."><plain>3-[(3)H]<z:chebi fb="105" ids="17234">glucose</z:chebi> was infused during the initial 3 h of the insulin clamp to determine rates of EGP and <z:chebi fb="105" ids="17234">glucose</z:chebi> disappearance (R(d)) </plain></SENT>
<SENT sid="8" pm="."><plain><z:chebi fb="0" ids="8228">Pioglitazone</z:chebi> reduced fasting plasma <z:chebi fb="105" ids="17234">glucose</z:chebi> (10.0 +/- 0.7 to 7.5 +/- 0.6 mmol/l, P &lt; 0.001) and HbA(1c) (7.8 +/- 0.4 to 6.7 +/- 0.3%, P &lt; 0.001) despite <z:hpo ids='HP_0004324'>increased body weight</z:hpo> (83 +/- 3 to 86 +/- 3 kg, P &lt; 0.001) </plain></SENT>
<SENT sid="9" pm="."><plain>During the 3-h insulin clamp period before <z:chebi fb="105" ids="17234">glucose</z:chebi> ingestion, <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> improved R(d) (6.9 +/- 0.5 vs. 5.2 +/- 0.5 mg </plain></SENT>
<SENT sid="10" pm="."><plain>kg(-1) </plain></SENT>
<SENT sid="11" pm="."><plain>min(- 1), P &lt; 0.001) and insulin-mediated suppression of EGP (0.21 +/- 0.04 to 0.06 +/- 0.02 mg </plain></SENT>
<SENT sid="12" pm="."><plain>kg(-1) </plain></SENT>
<SENT sid="13" pm="."><plain>min(-1), P &lt; 0.01) </plain></SENT>
<SENT sid="14" pm="."><plain>Following <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> treatment, hepatic fat content decreased from 19.6 +/- 3.6 to 10.4 +/- 2.1%, (P &lt; 0.005), and SGU increased from 33.0 +/- 2.8 to 46.2 +/- 5.1% (P &lt; 0.005) </plain></SENT>
<SENT sid="15" pm="."><plain><z:chebi fb="0" ids="8228">Pioglitazone</z:chebi> treatment in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> 1) decreases hepatic fat content and improves insulin-mediated suppression of EGP and 2) augments splanchnic and peripheral tissue <z:chebi fb="105" ids="17234">glucose</z:chebi> uptake </plain></SENT>
<SENT sid="16" pm="."><plain>Improved splanchnic/peripheral <z:chebi fb="105" ids="17234">glucose</z:chebi> uptake and enhanced suppression of EGP contribute to the improvement in glycemic control in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
</text></document>